Sumatriptan Patent Expiration
Sumatriptan is Used for managing acute migraine episodes. It was first introduced by Glaxosmithkline
Sumatriptan Patents
Given below is the list of patents protecting Sumatriptan, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Tosymra | US9211282 | Formulations comprising triptan compounds | Jul 19, 2031 | Tonix Meds |
| Tosymra | US10603305 | Formulations comprising triptan compounds | Jun 16, 2030 | Tonix Meds |
| Tosymra | US11337962 | Formulations comprising triptan compounds | Jun 16, 2030 | Tonix Meds |
| Tosymra | US12090139 | Formulations comprising triptan compounds | Jun 16, 2030 | Tonix Meds |
| Tosymra | US9610280 | Formulations comprising triptan compounds | Jun 16, 2030 | Tonix Meds |
| Tosymra | US9974770 | Formulations comprising triptan compounds | Jun 16, 2030 | Tonix Meds |
| Tosymra | US8268791 | Alkylglycoside compositions for drug administration | May 09, 2026 | Tonix Meds |
| Tosymra | US8440631 | Compositions for drug administration | May 09, 2026 | Tonix Meds |
| Tosymra | US9283280 | Compositions for drug administration | May 09, 2026 | Tonix Meds |
| Imitrex |
US5554639 (Pediatric) | Medicaments |
Mar 10, 2014
(Expired) | Glaxosmithkline |
| Imitrex | US5554639 | Medicaments |
Sep 10, 2013
(Expired) | Glaxosmithkline |
| Imitrex |
US5307953 (Pediatric) | Single dose dispenser having a piercing member |
Jun 02, 2013
(Expired) | Glaxosmithkline |
| Imitrex | US5307953 | Single dose dispenser having a piercing member |
Dec 02, 2012
(Expired) | Glaxosmithkline |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Sumatriptan's patents.
Latest Legal Activities on Sumatriptan's Patents
Given below is the list recent legal activities going on the following patents of Sumatriptan.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27 | 14 May, 2024 | US10603305 |
| Change in Power of Attorney (May Include Associate POA) Critical
| 07 May, 2024 | US9974770 |
| Email Notification Critical
| 07 May, 2024 | US9974770 |
| Change in Power of Attorney (May Include Associate POA) Critical
| 25 Apr, 2024 | US11337962 |
| Email Notification Critical
| 25 Apr, 2024 | US11337962 |
| Change in Power of Attorney (May Include Associate POA) Critical
| 24 Apr, 2024 | US9610280 |
| Email Notification Critical
| 24 Apr, 2024 | US10603305 |
| Email Notification Critical
| 24 Apr, 2024 | US9610280 |
| Change in Power of Attorney (May Include Associate POA) Critical
| 24 Apr, 2024 | US9211282 |
| Change in Power of Attorney (May Include Associate POA) Critical
| 24 Apr, 2024 | US10603305 |
Sumatriptan's Family Patents
